 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Aug 17, 2021 |
| Title |
Response of SCLC to mutant KRAS or EGFR induction |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Lineage transformation between lung cancer subtypes is a poorly understood phenomenon associated with resistance to treatment and poor patient outcomes. Here, we aimed to model this transition in order to define underlying biological mechanisms and identify potential avenues for therapeutic intervention. Small cell lung cancer (SCLC) is neuroendocrine in origin and, in contrast to non-SCLC (NSCLC), rarely contains mutations that drive the MAPK pathway. Likewise, NSCLCs that transform to SCLC concomitantly with development of therapy resistance downregulate MAPK signaling, suggesting an inverse relationship between pathway activation and lineage state. To test this, we activated MAPK in SCLC through conditional expression of mutant KRAS or EGFR, which revealed suppression of the neuroendocrine differentiation program via ERK. We found that ERK induces the expression of ETS factors, phenocopying ERK-mediated effects on transformation into the NSCLC-like phenotype. ATAC-seq demonstrated ERK-driven changes in chromatin accessibility at putative regulatory regions and global chromatin rewiring at neuroendocrine and ETS transcriptional targets. Further, induction of ETS factors as well as suppression of neuroendocrine differentiation were dependent on histone acetyltransferase activities of CBP/p300. Overall, we describe how the ERK-CBP/p300-ETS axis promotes a lineage shift between neuroendocrine and non-neuroendocrine lung cancer phenotypes and provide rationale for the disruption of this program during transformation-driven resistance to targeted therapy.
|
| |
|
| Overall design |
Two SCLC cell lines (H82 and H2107) were transduced with doxycyline inducible lentivirial vectors containing either GFP, mutant EGFR (L858R) ot mutant KRAS (G12V). Cell were placed on doxcycline to induce gene expression, and RNA harvested at the points indicated for expression analysis using Affymetrix arrays. In total, three biological replcates were analyzed for each gene at three timepoints after addition of Dox: Day 0 (No Dox), Day 1, and Day 7 for a total of 54 samples. GFP at each time point serves as a reference.
|
| |
|
| Contributor(s) |
Lockwood WW, Inoue Y |
| Citation(s) |
34121659 |
| |
| Submission date |
Oct 30, 2020 |
| Last update date |
Aug 18, 2021 |
| Contact name |
William Lockwood |
| E-mail(s) |
wlockwood@bccrc.ca
|
| Phone |
6046758264
|
| Organization name |
BC Cancer
|
| Department |
Integrative Oncology
|
| Street address |
675 West 10th Avenue
|
| City |
Vancouver |
| State/province |
British Columbia |
| ZIP/Postal code |
V5Z 1L3 |
| Country |
Canada |
| |
|
| Platforms (1) |
| GPL16686 |
[HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array [transcript (gene) version] |
|
| Samples (54)
|
|
| Relations |
| BioProject |
PRJNA673357 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE160482_RAW.tar |
403.1 Mb |
(http)(custom) |
TAR (of CEL) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...